Who are the top shareholders of the Tarsons Products?

The top shareholders of Tarsons Products include Sanjive Sehgal with 26.98%, Clear Vision Investment Holdings Pte Limited at 23.42%, and 16 Foreign Institutional Investors holding a combined 9.52%. Individual investors own 15.3% of the shares.

The top shareholders of Tarsons Products include the promoters, with Sanjive Sehgal holding the highest stake at 26.98%. Additionally, Clear Vision Investment Holdings Pte Limited is the largest public shareholder, owning 23.42%. The company also has 16 Foreign Institutional Investors (FIIs) holding a combined 9.52% of the shares. Individual investors collectively hold 15.3% of the company's shares.

What does Tarsons Products do?

Tarsons Products Ltd is a small-cap company in the healthcare services industry, incorporated in 1983 and converted to a public company in 2021. As of March 2025, it reported net sales of ₹113 Cr and a net profit of ₹10 Cr, with a market cap of ₹2,028 Cr.

Overview:<BR>Tarsons Products Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History:<BR>Tarsons Products Limited was incorporated as Tarsons Products Private Limited in 1983 and was converted into a Public Limited Company on June 14, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 113 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 10 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 2,028 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 68.00<BR>- Industry P/E: 41<BR>- Dividend Yield: 0.52%<BR>- Debt Equity: 0.50<BR>- Return on Equity: 4.72%<BR>- Price to Book: 3.23<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are in the management team of Tarsons Products?

As of March 2023, the management team of Tarsons Products includes Sanjive Sehgal (Chairman & Managing Director), Rohan Sehgal (Whole-time Director), and several independent directors, along with Santosh Kumar Agrawal (CFO & Company Secretary). They oversee the company's governance and operations.

As of March 2023, the management team of Tarsons Products includes:<BR><BR>1. Sanjive Sehgal - Chairman & Managing Director<BR>2. Rohan Sehgal - Whole-time Director<BR>3. Gaurav Podar - Nominee<BR>4. Viresh Oberai - Independent Director<BR>5. Sucharita Basu - Independent Director<BR>6. Girish Paman Vanvari - Independent Director<BR>7. Santosh Kumar Agrawal - Chief Finance Officer & Company Secretary<BR><BR>These individuals play key roles in the governance and operational management of the company.

Has Tarsons Products declared dividend?

Yes, Tarsons Products Ltd has declared a 100% dividend, amounting to ₹2 per share, with an ex-date of September 20, 2024. However, the company has experienced negative total returns over various periods, indicating a decline in price performance despite the dividend declaration.

Tarsons Products Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 2<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.52%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.41%, the dividend return was 0%, resulting in a total return of -15.41%.<BR><BR>Over the past year, the price return was -8.35%, the dividend return was 0.47%, leading to a total return of -7.88%.<BR><BR>In the last 2 years, the price return was -33.53%, the dividend return was 0.35%, resulting in a total return of -33.18%.<BR><BR>For the 3-year period, the price return was -45.15%, the dividend return was 0.29%, culminating in a total return of -44.86%.<BR><BR>In the 4-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, both the price return and dividend return were 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Tarsons Products has declared a dividend, the total returns over various periods indicate a negative trend in price performance, with minimal contributions from dividends.

Who are the peers of the Tarsons Products?

Tarsons Products' peers include Metropolis Health, Suven Life Sciences, Thyrocare Technologies, and others, with varying management risks and growth rates. Tarsons has below-average growth and the lowest 1-year return at -23.12% among its peers.

Peers: The peers of Tarsons Products are Metropolis Healt, Suven Life Scie., Thyrocare Tech., Krsnaa Diagnost., Laxmi Dental, Vimta Labs, Suraksha Diagno., 3B Blackbio, and Sastasundar Ven.<BR><BR>Quality Snapshot: Excellent management risk is observed at Laxmi Dental, while Good management risk is found at Metropolis Healt and Thyrocare Tech. Average management risk is present at Krsnaa Diagnost., Suraksha Diagno., and 3B Blackbio, and the rest have Below Average management risk, including Tarsons Products, Suven Life Scie., and Sastasundar Ven. Growth is Good at Laxmi Dental and Vimta Labs, while Below Average growth is noted for Metropolis Healt, Suven Life Scie., Thyrocare Tech, Krsnaa Diagnost, and Tarsons Products, with Average growth at Sastasundar Ven. Capital Structure is Excellent at Metropolis Healt, Thyrocare Tech, Krsnaa Diagnost, and Sastasundar Ven, Good at Laxmi Dental and Suraksha Diagno., and the rest have Average or Below Average ratings.<BR><BR>Return Snapshot: Suven Life Scie. has the highest 1-year return at 118.45%, while Tarsons Products has the lowest at -23.12%, indicating a significant underperformance compared to its peers. Additionally, Krsnaa Diagnost, Suraksha Diagno., 3B Blackbio, and Prevest Denpro have negative six-month returns.

How big is Tarsons Products?

As of 24th July, Tarsons Products Ltd has a market capitalization of 2,127.00 Cr, with recent net sales of 392.42 Cr and a net profit of 29.77 Cr. The company's shareholder's funds are 612.86 Cr, and total assets amount to 972.18 Cr.

As of 24th July, Tarsons Products Ltd has a market capitalization of 2,127.00 Cr and is classified as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 392.42 Cr and a Net Profit of 29.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 612.86 Cr and Total Assets of 972.18 Cr.

When is the next results date for Tarsons Products?

The next results date for Tarsons Products is 12 August 2025.

The next results date for Tarsons Products is scheduled for 12 August 2025.

Are Tarsons Products latest results good or bad?

Tarsons Products' latest results are disappointing, with a Profit Before Tax of Rs -0.31 crore and a Profit After Tax of Rs 1.78 crore, both showing significant declines. The company's net sales and earnings per share have also dropped, leading to a 'Strong Sell' rating from MarketsMOJO, indicating a negative outlook.

The latest results for Tarsons Products are quite disappointing. The company has reported a significant decline in profitability, with a Profit Before Tax (PBT) of Rs -0.31 crore, which is a drastic drop of 104.3% compared to the average PBT of Rs 7.21 crore over the previous four quarters. Similarly, the Profit After Tax (PAT) has fallen to Rs 1.78 crore, marking a 76.1% decrease from the average PAT of Rs 7.44 crore.<BR><BR>Net sales have also decreased, standing at Rs 91.36 crore, which is a 6.9% decline from the average of Rs 98.11 crore. The earnings per share (EPS) have reached their lowest point in five quarters at Rs 0.33, indicating a troubling trend in profitability. Additionally, the company's cash and cash equivalents have decreased to Rs 8.45 crore, reflecting a deterioration in short-term liquidity.<BR><BR>Overall, these results suggest a concerning downturn for Tarsons Products, and the stock has been rated as a 'Strong Sell' by MarketsMOJO, further emphasizing the negative outlook.

Is Tarsons Products technically bullish or bearish?

As of 18 August 2025, Tarsons Products has shifted to a bearish trend with moderate strength, indicated by bearish MACD and Bollinger Bands across multiple time frames, along with significant underperformance against the Sensex.

As of 18 August 2025, the technical trend for Tarsons Products has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish daily moving average. The KST is mildly bearish on the weekly and bearish on the monthly, while the Dow Theory shows no trend on the weekly and mildly bearish on the monthly. The stock has underperformed significantly against the Sensex over various periods, further supporting the bearish outlook.

How has been the historical performance of Tarsons Products?

Tarsons Products has shown strong sales growth from 228.91 Cr in March 2021 to 392.41 Cr in March 2025, but profitability metrics, including profit before tax and profit after tax, have declined during the same period. Total assets increased significantly, while total debt rose sharply, indicating higher leverage.

Answer:<BR>The historical performance of Tarsons Products shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Tarsons Products has experienced notable changes in its financial performance from March 2021 to March 2025. Net sales increased from 228.91 Cr in March 2021 to 392.41 Cr in March 2025, indicating a strong growth trajectory. However, the total operating income followed a similar trend, rising from 228.91 Cr to 392.41 Cr during the same period. The total expenditure also rose significantly, from 125.48 Cr in March 2021 to 281.69 Cr in March 2025. Operating profit (PBDIT) peaked at 161.16 Cr in March 2022 but decreased to 126.68 Cr by March 2025. Profit before tax saw a decline from 92.43 Cr in March 2021 to 44.80 Cr in March 2025, while profit after tax also dropped from 68.87 Cr to 29.77 Cr in the same timeframe. The company's total assets increased from 295.95 Cr in March 2021 to 1,080.04 Cr in March 2025, reflecting substantial growth in its asset base. Conversely, total debt rose from 3.27 Cr to 328.56 Cr, indicating a significant increase in leverage. Overall, while Tarsons Products has shown growth in sales and assets, profitability metrics have declined in recent years.

Should I buy, sell or hold Tarsons Products?

Is Tarsons Products overvalued or undervalued?

As of December 1, 2025, Tarsons Products is considered overvalued with a PE ratio of 59.27, significantly higher than its peers, and has underperformed the market with a year-to-date return of -43.36%.

As of 1 December 2025, the valuation grade for Tarsons Products has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 59.27, an EV to EBIT of 40.66, and an EV to EBITDA of 13.33. These ratios suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities.<BR><BR>In comparison to its peers, Tarsons Products' PE ratio is significantly higher than that of Finolex Industries, which stands at 22.79, indicating a stark contrast in valuation. Additionally, while Tarsons Products has a PEG ratio of 0.00, this is not favorable when compared to peers like Shaily Engineers, which has a PEG of 0.83, suggesting that Tarsons may not be justifying its high valuation through growth. The company's recent stock performance has been poor, with a year-to-date return of -43.36%, contrasting sharply with the Sensex's 9.60% return, further reinforcing the notion of overvaluation.

Which are the latest news on Tarsons Products?

Why is Tarsons Products falling/rising?

As of 03-Dec, Tarsons Products Ltd's stock price is at 230.85, down 0.4 (-0.17%), with a significant decline in investor participation and underperformance against the Sensex. The company faces financial challenges, including a -30% profit decrease and a poor long-term growth rate, leading to reduced institutional confidence and an expensive valuation relative to peers.

As of 03-Dec, Tarsons Products Ltd's stock price is currently at 230.85, reflecting a decrease of 0.4 (-0.17%). The stock has shown a trend of falling, particularly after experiencing two consecutive days of gains. This decline is supported by a significant drop in investor participation, as evidenced by a delivery volume of 79.1k on December 2, which has fallen by 94.74% compared to the 5-day average. <BR><BR>In terms of performance, the stock has underperformed against the benchmark Sensex over various periods, including a staggering -68.43% over the last three years. Additionally, the stock has generated a return of -47.10% over the past year, while its profits have decreased by -30%. The company's financial health is also concerning, with a poor long-term growth rate of -18.84% in operating profit over the last five years and a low return on capital employed (ROCE) of 3.9. <BR><BR>Moreover, institutional investors have reduced their stakes by 3.27% in the previous quarter, indicating a lack of confidence from those with more resources to analyze the company's fundamentals. The stock's valuation appears expensive relative to its performance, trading at a discount compared to its peers' average historical valuations. All these factors contribute to the stock's current downward trend.